AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 233 min read$ABBV

AbbVie (ABBV) Gains FDA Nod for At-Home Skyrizi Induction in Cro

AbbVie (ABBV) received FDA approval for an at-home subcutaneous induction regimen for its drug Skyrizi, allowing adults with moderate to severe Crohn’s disease to start treatment at home. The company offers a 2.34% dividend yield with a high payout ratio of 85% and a 3-year dividend growth rate of 5.2%. AbbVie's GF Value™ suggests the stock is modestly overvalued at $222.72 versus the current price of $286.20.

Original reporting
gurufocus.com
Published Oct 23, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The approval could drive incremental revenue and improve patient adherence, supporting the stock’s valuation despite a high dividend payout ratio.

02

Market read

First‑report regulatory approval for a major drug indication; likely to move ABBV stock positively.

03

What to watch

Potential reimbursement challenges and the high dividend payout ratio could limit upside.

Relevance 7/10Novelty 9/10Timing: today

Background

AbbVie announced the FDA nod for an at‑home Skyrizi induction, adding to its immunology portfolio alongside Rinvoq and Humira.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie received FDA approval for a new at‑home subcutaneous induction regimen for Skyrizi in Crohn’s disease.

Expected impact

likely upward pressure as investors price in the new indication and potential sales uplift

Evidence & confidence

First‑report FDA nod for a high‑growth indication; adds a differentiated delivery option that can increase adoption and market share.

Market effects

Sector

Strengthens the broader immunology/biotech sector by highlighting innovative delivery methods.

Regional

U.S. biotech equities may see modest gains as the approval underscores FDA willingness to endorse novel regimens.

Global

May influence global competitors developing similar at‑home biologic delivery platforms.

Counterpoint

What could challenge this read

If the new regimen fails to gain payer acceptance, the stock could face disappointment despite the approval.

Key entities

  • company
    AbbVie Inc.

    U.S. biopharmaceutical company receiving FDA approval for Skyrizi.

Read at source← All news

StoryFDA approves subcutaneous induction regimen of AbbVie’s SKYRIZI for Crohn’s disease

Also covered by

6 outlets

Related articles

OCT 23
$ABBVHigh

Abbvie Announces U.S. Fda Approval of Subcutaneous Induction Regimen for Skyrizi for Adults with Moderately to Severely Active Crohn's Disease

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval follows positive Phase 3 trial results, showing significant clinical remission and endoscopic response in patients. SKYRIZI can now be administered at home using an on-body injector, with induction doses at weeks 0, 2, 4, and 8, followed by maintenance dosing every eight weeks.

marketscreener.com2 min
OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SK

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on positive Phase 3 AFFIRM trial results, showing superior clinical remission and endoscopic response at week 12 compared to placebo, especially in treatment-naïve patients. The subcutaneous form allows for at-home administration using an on-body injector.

gurufocus.com2 min
OCT 23
$ABBVHigh

FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi

AbbVie (ABBV) received FDA approval for a subcutaneous induction regimen of Skyrizi for Crohn's disease. The regimen involves 720 mg doses at weeks 0, 2, 4, and 8, with maintenance doses every 8 weeks. The approval is based on Phase 3 trial results showing 56% clinical remission vs. 30% for placebo. The FDA also updated prescribing info to remove mandatory TB testing. Skyrizi is approved for several autoimmune diseases.

investing.com2 min
OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

AbbVie's SKYRIZI® (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on Phase 3 AFFIRM trial results showing superior clinical remission and endoscopic response at week 12 compared to placebo, with no new safety risks identified. The subcutaneous option allows for at-home treatment using an on-body injector.

news.abbvie.com3 min